Direct thrombin inhibitors

Expert Opinion on Pharmacotherapy

Volumn 4, Issue 5, 2003, Pages 653-666

  Kaplan, Karen L ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Argatroban; Bivalirudin; Hirudin; Melagatran; Thrombin; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ACTIVATED PROTHROMBIN COMPLEX; ANTITHROMBIN; ARGATROBAN; DALTEPARIN; DESMOPRESSIN ACETATE; DESULFATOHIRUDIN; EFEGATRAN; ENOXAPARIN; FIBRINOGEN; HEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; INOGATRAN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; NAPSAGATRAN; PROTAMINE; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; SERINE PROTEINASE; STREPTOKINASE; THROMBIN INHIBITOR; TIROFIBAN; VITAMIN K GROUP; WARFARIN; XIMELAGATRAN;

ANTICOAGULATION; CLINICAL TRIAL; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; CORONARY ARTERY THROMBOSIS; DEEP VEIN THROMBOSIS; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME INHIBITION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; REVIEW; STROKE; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ANTITHROMBINS; CORONARY DISEASE; EXPERT TESTIMONY; HALF-LIFE; HIRUDINS; HUMANS; METABOLIC CLEARANCE RATE; PEPTIDE FRAGMENTS; PIPECOLIC ACIDS; RECOMBINANT PROTEINS; THROMBIN; VENOUS THROMBOSIS;

EID: 0038474020     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.4.5.653     Document Type: Review

References (124)

1. MANN KG, JENNY RJ, KRISHNASWAMY S: Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann. Rev. Biochem. (1988) 57:915-956.
2. DAVEY MG, LUSCHER EF: Actions of thrombin and other coagulant and proteolytic enzymes on blood platelets. Nature (1967) 216:857-858.
3. ESMON NL, OWEN WG, ESMON CT: Isolation of a membrane-bound cofactor for thrombin-catalyzed activation of protein C. J. Biol. Chem. (1982) 257:859-864.
4. ESMON CT: The roles of protein C and thrombomodulin in the regulation of blood coagulation. J. Biol. Chem. (1989) 264:4743-4746.
5. BAJZAR L, MANUAL & NESHEIM ME: Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. (1995) 270:14477-14484.
6. COUGHLIN SR. How thrombin 'talks' to cells. Molecular mechanisms and roles in vivo. Arterioscler. Thromb. Vasc. Biol. (1998) 18:514-518.
7. ROSENBERG RD, DAMUS PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J. Biol. Chem. (1973) 248:6490-6505.
8. WEITZ JI: Drug therapy: low-molecular weight heparins. N. Engl. J. Med. (1997) 337:688-698.
9. CHOAY J, PETITOU M, LORMEAU JC et al.: Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem. Biophys. Res. Commun. (1983) 116:492-499.
10. LIU CY, NOSSEL HL, KAPLAN KL: The binding of thrombin by fibrin. J. Biol. Chem. (1979) 254:10421-10425.
11. WEITZ JI, HUDOBA M, MASSEL D et al.: Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J. Clin. Invest. (1990) 86:385-391.
12. FRANCIS CW, MARKHAM RE Jr, BARLOW GH et al.: Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J. Lab. Clin. Med. (1983) 102:220-230.
13. BAJUSZ S, BARABAS E, TOLNAY P et al.: Inhibition of thrombin and trypsin by tripeptide aldedydes. Int. J. Pep. Pro. Res. (1978) 12:217-221.
14. BODE W, MAYR I, BAUMANN U et al.: The refined 1.9 Å crystal structure of human α-thrombin: interaction with D-Phe-Pro-Arg chloromethylketone and significance of the Tyr-Pro-Pro-Trp insertion segment. EMBO (1989) 8:3467-3475.
15. RYDEL TJ, RAVICHANDRAN KG, TULINSKY A et al.: The structure of a complex of recombinant hirudin and human alpha-thrombin. Science (1990) 249:277-280.
16. KAPLAN KL, FRANCIS CW: Heparin-induced thrombocytopenia. Blood Rev. (1999) 13:1-7.
17. KELTON JG, SMITH JW, WARKENTIN TE et al.: Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood (1994) 83:3232-3239.
18. AMIRAL J, BRIDEY F, WOLF M et al.: Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. (1995) 73:21-28.
19. WARKENTIN TE, ELAVATHIL LJ, HAYWARD CP et al.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. (1997) 127:804-812.
20. MAGNANI HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb. Haemost. (1993) 70:554-561.
21. YUDELMAN IM, NOSSEL HL, KAPLAN KL et al.: Plasma fibrinopeptide A levels in symptomatic venous thromboembolism. Blood (1978) 51:1189-1195.
22. THEROUX P, WATERS D, LAM J et al.: Reactivation of unstable angina after the discontinuation of heparin. N. Engl. J. Med. 327:141-145.
23. LINDER R. OLDGREN J, EGBERG N et al.: The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease (Comment). Eur. Heart J. (1999) 20:506-518.
24. HAUPTMANN J: Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. Eur. J. Clin. Pharmacol. (2002) 57:751-758.
25. HAYCRAFT J: Uber die einwirkung eines secretes des officinellen blutegels auf die gerinnbarkeit des blutes. Arch. Exp. Path. Pharmak. (1884) 18:20-24.
26. STONE SR. HOFSTEENGE J: Kinetics of the inhibition of thrombin by hirudin. Biochemistry (1986) 25:4622-4627.
27. STONE SR, BRAUN PJ, HOFSTEENGE J: Identification of the regions of α-thrombin involved in its interactions with hirudin. Biochemistry (1987) 26:4617-4622.
28. TULINSKY A. Molecular interactions of thrombin. Sem. Thromb. Hemost. (1996) 22:117-124.
29. 131I] Lepirudin in baboons. J. Pharm. Sci. (1999) 88:523-529.
30. MEYER BH, LUUS HG, MULLER FO et al.: The pharmacology of recombinant hirudin, a new anticoagulant. S. Afr. Med. J. (1990) 78:268-270.
31. CARDOT J, LEFEVRE G, GODBILLON J: Pharmacokinetics of rec-hirudin in healthy volunteers after intravenous administration. J. Pharmacokinet. Biopharm. (1994) 22:147-156.
32. ZOLDHELYI P, WEBSTER MWI, FUSTER V et al.: Thrombosis, platelets, and coagulation: recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation (1993) 88:2015-2022.
33. VERSTRAETE M, NURMOHAMED M, KIENAST J et al.: Biologic effects of recombinant hirudin (CGP 39393) in human volunteers. J. Am. Coll. Cardiol. (1993) 22:1080-1088.
34. TRIPODI A, CHANTARANGKUL V, ARBINI AA et al.: Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb. Haemost. 1993 70:286-288.
35. POTZSCH B, HUND S, MADLENER K et al.: Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay. Thrombosis Research (1997) 86:373-383.
36. BICHLERJ, BAYNES JJ, THORPE SR: Catabolism of hirudin and thrombin-hirudin complexes. Biochem. J. (1993) 296:771-776.
37. HUHLE G, HOFFMANN U, SONG X et al.: Immunologic response to recombinant hirudin in HIT Type II patients during long-term treatment. Br. J. Haematol. (1999) 106:195-201.
38. SONG X, HUHLE G, WANG L et al.: Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation (1999) 100:1528-1532.
39. HUHLE G, LIEBE V, HUDEK R, HEENE DL: Anti-r-hirudin antibodies reveal clinical relevance through direct functional inactivation of r-hirudin or prolongation of r-hirudid's plasma half-life. Thromb. Haemost (2001) 85:936-938.
40. EICHLER P, FRIESEN H-J, LUBENOW N et al.: Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT, and clinical relevance. Blood (2000) 96:2373-2378.
41. MARAGANORE JM, BOURDON P, JABLONSKI J et al.: Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry (1990) 29:7095-7101.
42. PARRY MA, MARAGANORE JM STONE SR: Kinetic mechanism for the interaction of Hirulog with thrombin. Biochemistry (1994) 33:14807-14814.
43. ROBSON R: The use of bivalirudin in patients with renal impairment. J. Invas. Cardiol. (2000) 12:33F-36F.
44. 2-[(3-methyl- 1,2,3,4-tetrahydro-8-quinolinyl)sulfonyl]- L-arginyl)]-2-piperidinecarboxylic acid. Biochemistry (1984) 23:85-90.
45. BERRY CN, GIRARDOT C, LECOFFRE C et al.: Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Haemost. (1994) 72:381-386.
46. HANTGAN RR, JEROME WG, HURSTING MJ: No effect of clot age or thrombolysis on argatroban's inhibition of thrombin. Blood (1998) 92:2064-2074.
47. HURSTING MJ, ALFORD KL, BECKER JC et al.: Novastan (brand of argatroban): a small-molecule direct thrombin inhibitor. Sem. Thromb. Hemost. (1997) 23:503-516.
48. McKEAGE K, PLOSKER GL: Argatroban. Drugs (2001) 61:515-522.
49. SWAN SK, HURSTING MJ: The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy (2000) 20:318-329.
50. GUSTAFSSON D, ANTONSSON T, BYLUND R et al.: Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb. Haemost. (1998) 79:110-118.
51. ERIKSSON UG, JOHANSSON L, FRISON L et al.: Single and repeated oral dosing of H376/95, a prodrug of the direct thrombin inhibitor melagatran, to young healthy male subjects. Blood (1999) 94(Suppl. 1):P101.
52. ERIKSSON H, ERIKSSON UG, FRISON L et al.: Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thromb. Haemost. (1999) 81:358-363.
53. ERIKSSON UG, ERIKSSON-LEPKOWSKA M, OHLSSON L et al.: The pharmacokinetics and pharmacodynamics of ximelagatran in patients with mild-to-moderate impairment of liver function. Blood (2001) 98:46a.
54. SARICH TC, TENG I, PETERS G et al.: Lack of effect of obesity on the pharmacokinetics and pharmacodynamics of melagatran after oral administration of ximelagatran. Blood (2001) 98:45a.
55. ERIKSSON UG, SAMUELSSON O, ATTMAN P-O et al.: The pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran in patients with severe renal impairment. Blood (2001) 98:268a.
56. LEBRAZI J, ELALAMY I, SAMAMA MM: Inhibitory effect of melagatran and hirudin on clot-bound thrombin. Thromb. Haemost. (2001) 86:CD3576.
57. LINDER F. FREBELIUS S, JANSSON K, SWEDENBORG J: More profound inhibition of endothelial cell mediated APC generation by low molecular mass thrombin inhibitors than by other thrombin inhibitors. Thromb. Haemost. (2001) 86:P511.
58. ERIKSSON UG, FRISON L, GUSTAFSSON D et al.: The pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H376/95), in orthopaedic surgery patients treated to prevent deep venous thrombosis and pulmonary embolism. Thromb. Haemost. (2001) 86:P3092.
59. ERIKSSON UG, FRISON L, GUSTAFSSON D et al.: Effect of melagatran, the active form of the oral direct thrombin inhibitor, ximelagatran (pINN, formerly H376/95), on activated partial thromboplastin time in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism. Thromb. Haemost. (2001) 86:P3093.
60. TEGER-NILSSON AC, BYLUND R, GUSTAFSSON D et al.: In vitro effects of inogatran, a selective low molecular weight thrombin inhibitor. Thromb. Res. (1997) 85:133-145.
61. SMITH GF, SHUMAN RT, CRAFT TJ et al.: A fimily of arginal thrombin inhibitors related to efegatran. Sem. Thromb. Haemost. (1996) 22:173-183.
62. ROUX S, TSCHOPP T, BAUMGARTNER HR: Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model. J. Pharm. Exp. Therapies (1996) 277:71-78.
63. GREINACHER A, JANSSENS U, BERG G et al.: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation (1999) 100:587-593.
64. GREINACHER A, VOLPEL H, JANSSENS U et al.: Recombinant hirudin (Lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia. A prospective study. Circulation (1999) 99:73-80.
65. LEWIS B, WALLIS D, BERKOWITZ S et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 103:1838-1843.
66. LEWIS BE, MATTHAI WH Jr, COHEN M et al.: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter. Cardiovasc. Interv. (2002) 57:177-184.
67. GREINACHER. A, EICHLER P, LUBENOW N et al.: Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood (2000) 96:846-851.
68. LUBENOW N, EICHLER P, LEITZ T: Meta-analysis of three prospective studies of lepirudin in the prevention of thrombosis in patients with heparin-induced thrombocytopenia. Blood (2002) 100:501a.
69. LUBENOW N, EICHLER P, GREINACHER A. Results of a large drug monitoring program confirms the safety and efficacy of Refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (HIT). Blood (2002) 100:502a.
70. DEITCHER SR, TOPOULOS AP, BARTHOLOMEW JR, KICHUK-CHRISANT MR: Lepirudin anticoagulation for heparin-induced thrombocytopenia (Clinical and Laboratory Observations). J. Pediatr. (2002) 140:264-266.
71. MATTHAI WJ, HURSTING M, LEWIS B: Argatroban use in patients with a history of heparin-induced thrombocytopenia who require acute anticoagulation. Blood (2001) 98:45a.
72. SMYTHE MA, WARKENTIN TE, STEPHENS JL, ZAKALIK D, MATTON JC: Venous limb gangrene during overlapping therapy with warfarin and a direct thrombin inhibitor for immune heparin-induced thrombocytopenia. Am. J. Hematol. (2002) 71:50-52.
73. SHETH SB, DICICCO RA, HURSTING MJ et al.: Interpreting the International Normalized Ratio in individuals receiving argatroban and warfarin. Thromb. Haemost. (2001) 85:435-440.
74. SERRUYS PW, HERRMAN J-PR, SIMON R et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. (1995) 333:757-763.
75. Organization to assess strategies for ischemic syndromes (OASIS) investigators: comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischemia without ST elevation: a pilot study. Circulation (1997) 96:769-777.
76. Organization to assess strategies for ischemic syndromes (OASIS-2) Investigators: effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularization procedures in patients with myocardial infarction without ST elevation: a randomized trial. Lancet (1999) 353:429-438.
77. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators: a comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. (1996) 335:775-782.
78. ROE MT, GRANGER CB, PUMA JA et al.: Comparison of benefits and complications of Hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention (Brief Reports). Am. J. Cardiol. (2001) 88:1403-1406.
79. MEHTA SR. EIKELBOOM JW, RUPPRECHT H-J et al.: Efficacy of hirudin in reducing cardiovascular events in patients with acute coronary syndromes undergoing early percutaneous intervention. Eur. Heart J. (2001) 23:117-123.
80. ANTMAN E: Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. TIMI 9A investigators. Circulation 90:1624-1630.
81. NEUHAUS K-L, VON ESSEN R, TEBBE U et al.: Safety observations from the pilot phase of the randomized r-Hirudin for Improvevment of Thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardolischer Krankenhausartze (ALKK). Circulation (1994) 90:1638-1642.
82. The global use of strategies to open occluded coronary arteries (GUSTO) IIb investigators: randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation (1994) 90:1631-1637.
83. ANTMAN E: Hirudin in acute myocardial infarction. TIMI 9B Investigators. Circulation (1996) 94:911-921.
84. METZ BK, WHITE HD, GRANGER CB et al.: Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb trial. JACC (1998) 31:1493-1498.
85. TOPOL EJ, BONAN R, JEWITT D et al.: Use of a direct antithrombin, Hirulog, in place of heparin during coronary angioplasty. Circulation (1993) 87:1622-1629.
86. BITTL JA, STRONY J, BRINKER JA et al.: Treatment with Bivalirudin (Hirulog) as compared with heparin during angioplasty for unstable or postinfarction angina. N. Engl. J. Med. (1995) 333:764-769.
87. LINCOFF AM, BITTL JA, HARRINGTON RA et al.: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. JAMA (2003) 289:853-863.
88. BURCHENAL JE, MARKS DS, TIFT MANN J et al.: Effect of direct thrombin inhibition with Bivalirudin (Hirulog) on restenosis after coronary angioplasty. Am. J. Cardiol. (1998) 82:511-515.
89. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. HERO-2 trial investigators. Lancet (2001) 358:1855-1863.
90. LEWIS BE: Results of Phase II/III trial of argatroban anticoagulation during PTCA of patients with heparin-induced thrombocytopenia (HIT). Circulation (1997) 96(Suppl.):217.
91. LEWIS BE, COHEN M, LEYA F et al.: Argatroban use in patients with heparin-induced thrombocytopenia during percutaneous coronary intervention. Chest (2000) 118 (Suppl.):216.
92. LEWIS BE, COHEN M, MOSES J et al.: Argatroban anticoagulation during initial and repeat percutaneous coronary intervention (PCI) in patients with heparin-induced thrombocytopenia. Am. J. Cardiol. (2000) 86 (Suppl. 8A):14i.
93. IQBAL O, LEWIS BE, AHMAD S et al.: Dosage adjustment of argatroban justified in combination with glycoprotein IIb/IIIa receptor antagonist: laboratory and clinical implications. Blood (2001) 98:48a.
94. ANDERSEN K, DELLBORG M, EMANUELSSON H, GRIP L, SWEDBERG K: Thrombin inhibition with inogatran for unstable pectoris: evidence for reactivated ischaemia after cessation of short-term treatment. Coron. Artery Dis. (1996) 7:673-681.
95. A low molecular weight, selective thrombin inhibitor, inogatran, versus heparin, in unstable coronary artery disease in 1209 patients. A double-blind, randomized, dose-finding study. Thrombin Inhibition in myocardial ischaemia (TRIM) study group. Eur. Heart J. (1997) 18:1416-1425.
96. KLOOTWIJK P, LENDERINK T, MEIJ S et al.: Anticoagulant properties, clinical efficacy and safety of efegatran, a direct thrombn inhibitor, in patients with unstable angina (Comment). Eur. Heart J. (1999) 20:1101-1111.
97. Multicenter, dose-ranging; study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: the Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. The prime investigators. Am. Heart J. (2002) 14:95-105.
98. FUNG AY, LORCH G, CAMBIER PA et al.: Efegatran sulfate as an adjunct to streptokinase versus heparin as an adjunct to tissue plasminogen activator in patients with acute myocadial infarction. ESCALAT Investigators. Am. Heart J. (1999) 138:696-704.
99. Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta-analysis based on individual patients' data. Direct thrombin inhibitor trialists' collaborative group. Lancet (2002) 359:294-302.
100. ERIKSSON BI, KALEBO P, EKMAN S et al.: Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb. Haemost. (1994) 72:227-231.
101. ERIKSSON BI, EKMAN S, LINDBRATT SIV et al.: Prevention of thromboembolism with use of recombinant hirudin: Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J. Bone Joint Surg. (1997) 79 A:326-333.
102. ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al.: A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. (1997) 337:1329-1335.
103. GINSBERG JS, NURMOHAMED MT, GENT M et al.: Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation (1994) 90:2385-2389.
104. BERGQVIST D, HOLMDAHL I, SOLHAUG J-H et al.: Efficacy and safety of subcutaneous melagatran and oral ximelagatran (pINN, formerly H376/95) as prophylaxis against thromboembolic complications following general abdominal surgery. Thromb. Haemost. (2001) 86:OC1020.
105. HEIT JA, COLWELL CW, FRANCIS CW et al.: Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement. Arch Int. Med. (2001) 161:2215-2221.
106. ERIKSSON BI, ARFWIDSSON A-C, FRISON L et al.: A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. Thromb. Haemost. (2002) 87:231-237.
107. ERIKSSON BI, BERGQVIST D, KALEBO P et al.: Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet (2002) 360:1441-1447.
108. FRANCIS CW, DAVIDSON BL, BERKOWITZ SD et al.: Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Ann. Intern. Med. (2002) 137:648-655.
109. COLWELL CW, BERKOWITZ SD, DAVIDSON BL et al.: Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and enoxaparin to prevent venous thromboembolism after total hip arthroplasty. Blood (2001) 98:706a.
110. ERIKSSON H, WAHLANDER K, GUSTAFSSON D et al.: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J. Thromb. Haemost. (2003) 1:41-47.
111. WAHLANDER K, LAPIDUS L, OLSSON C et al.: THRIVE IV: an open-label, pilot study of the treatment of pulmonary embolism with the oral direct thrombin inhibitor ximelagatran. Blood (2001) 98:268a-269a.
112. HARENBERG J, INGRID J, TIVADAR F: Treatment of venous thromboembolism with the oral thrombin inhibitor, ximelagatran. Isr. Med. Assn. J. (2002) 4:1003-1005.
113. KARIO K, KODAMA K, KOIDE M et al.: Thrombin inhibition in the acute phase of stroke using argatroban. Blood Coagul. Fibrinolysis (1995) 6:423-427.
114. KARIO K, MATSUO T, HOSHIDE S et al.: Effect of thrombin inhibition in vascular dementia and saent cerebrovascular disease. Stroke (1999) 30:1033-1037.
115. MARUKI Y, ONODA A, MATSUZAKI M et al.: A specific thrombin inhibitor (argatroban) ameliorated cerebral blood flow in the patients with acute cerebral infarction. Keio J. Med. (2000) 49(Suppl. 1):A138-A140.
116. PETERSEN P: A long-term follow-up of ximelagatran as an oral anticoagulant for the prevention of stroke and systemic embolism in patients with atrial fibrillation. SPORTIF II and IV investigators. Blood (2001) 98:706a-707a.
117. HALPERIN JL: Ximelagatran compared with warfarin for the prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation: rationale, objectives, design and organization of two long-term clinical trials (SPORTIF III & V). SPORTIF III and V investigators. Blood (2002) 100:123B.
118. FRANK RD, FARBER H, STEFANIDIS I et al.: Hirudin elimination by hemofiltration: a comparative in vitro study of different membranes. Kidney Int. (1999) 72:S41-S45.
119. ELG M, CARLSSON S, GUSTAFSSON D: Effect of activated prothrombin complex concentrate or recombinant Factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor. Thromb. Res. (2001) 101:145-157.
120. FAREED J, WALENGA J, BENDER N et al.: Bleeding effects of antithrombin drugs can be neutralized by activated FVIIa (NovoSevenR) and combinations of other plasma-derived products. Thromb. Haemost. (2001) 86:P2614.
121. ELG M, CARLSSON S, GUSTAFSSON D: Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthetized rats and rabbits. Thromb. Res. (2001) 101:159-170.
122. IBBOTSON SH, GRANT PJ, KERRY R et al.: The influence of infusions of 1-desamino-8-D-arginine vasopressin (DDAVP) in vivo on the anticoagulant effect of recombinant hirudin (CGP39393) in vitro. Thromb. Haemost. (1991) 65:64-66.
123. BUTLER KD, DOLAN SL, TALBOT MD, WALLIS RB: Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP39393) on bleeding in the rat. Blood Coagul. Fibrinolysis (1993) 4:459-464.
124. BOVE CM, CASEY B, MARDER VJ: DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb. Haemost. (1996) 75:471-475.